ERBB2 and breast carcinoma: Further analyses of MEMO1 levels in breast cancer subtypes determined that MEMO1 overexpression is more prominent in triple negative (TNBC) and HER2+ (HER2-enriched) breast tumors than in the luminal subtype (Figure 1C).